California Lawyer Features Burke's Participation in White Collar Defense Roundtable
March 13, 2014
California Lawyer Magazine
Partner Frank Burke was part of a wide-ranging roundtable discussion among senior defense attorneys and a federal prosecutor on emerging trends in white collar defense which was featured in the March 2014 edition of California Lawyer Magazine. The panel covered trends in residential mortgage backed securities, health care fraud, off-label pharmaceutical marketing, financial industry fraud, and emerging investigation techniques.
Regarding the proliferation of government prosecutions and False Claims Act whistleblower cases in health care and life sciences, Frank noted that “We’ve got a Medicare Fraud Strike Force and the Department of Health and Human Services at the federal level; at the state level we’ve got Medicaid fraud control units…[O]n top of all that you have whistleblowers… So the combination of very active state and federal enforcement and regulatory agencies and whistleblowers has led to a real explosion that I don’t think is going to abate anytime soon. Health care is such a large percentage of the economy.”
Regarding FCPA trends, Frank noted prosecutions of pharmaceutical and medical device makers concerning payments to doctors and hospitals in several foreign countries, and noted: “We’re also seeing more emphasis on prosecutions of foreign companies, which requires finding pieces of U.S. jurisdiction, either by charging them with conspiracy to act with a U.S. company, or perhaps payments that flowed through U.S. bank accounts, or e-mails sent through computers located on U.S. soil.”
Regarding the proliferation of government prosecutions and False Claims Act whistleblower cases in health care and life sciences, Frank noted that “We’ve got a Medicare Fraud Strike Force and the Department of Health and Human Services at the federal level; at the state level we’ve got Medicaid fraud control units…[O]n top of all that you have whistleblowers… So the combination of very active state and federal enforcement and regulatory agencies and whistleblowers has led to a real explosion that I don’t think is going to abate anytime soon. Health care is such a large percentage of the economy.”
Regarding FCPA trends, Frank noted prosecutions of pharmaceutical and medical device makers concerning payments to doctors and hospitals in several foreign countries, and noted: “We’re also seeing more emphasis on prosecutions of foreign companies, which requires finding pieces of U.S. jurisdiction, either by charging them with conspiracy to act with a U.S. company, or perhaps payments that flowed through U.S. bank accounts, or e-mails sent through computers located on U.S. soil.”
Related News
September 18, 2026
In the News
Patrick Daugherty Authors Article on Navigating Proposed SEC Crypto Asset Regulations
Foley & Lardner LLP partner Patrick Daugherty authored the Columbia Law School’s Blue Sky Blog article, “How to Advise Token Developers in Light of Proposed SEC Regulation Crypto Assets.”
September 17, 2026
In the News
Foley Featured in Law.com for Guiding Kontoor Brands in Sale of Lee®
Foley & Lardner LLP partner Bryan Schultz is featured for leading the Foley deal team which advised Kontoor Brands in the sale of its Lee® business in Law.com's “How the Deal Got Done” series.
September 15, 2026
In the News
David Rosen Shares Insights on FDA Efforts to Accelerate Human Clinical Trials
Foley & Lardner LLP partner David Rosen shared insights in the recent Law360 article, “FDA Seeks Applications For Project To Speed Up Human Trials,” on the FDA's pilot program pairing pharmaceutical companies with research institutions to accelerate human clinical trials.